Lung Cancer: Lung Cancer III |

Effectiveness and Safety of Poly (ADP-ribose) Polymerase Inhibitors in Cancer Therapy: A Systematic Review and Meta-analysis FREE TO VIEW

Zhengqiang Bao; Chao Cao; Bao-ping Tian; Zhihua Chen; Wen Li; Huahao Shen; Songmin Ying
Author and Funding Information

Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;149(4_S):A312. doi:10.1016/j.chest.2016.02.325
Text Size: A A A
Published online


SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: To evaluate the efficiency and safety of PARP inhibitors in cancer therapy.

METHODS: We carried out a comprehensive search to identify potential articles in PUBMED and EMBASE up to January 2015, using the search terms: “PARP inhibitors” or “Olaparib” or “Iniparib” or “Veliparib” or “Rucaparib” or “Niraparib” or “Talazoparib” and “cancer” or “tumor” or “carcinoma”, limited to clinical trials. The hazard ratio (HR) of the median OS and median PFS with 95% confidence intervals (CIs), and adverse events were extracted from most of the trials to carry out the meta analysis.

RESULTS: According to our study, PARP inhibitors could clearly improve progression-free survival (PFS), especially in patients with BRCA mutation. However, our study showed no significant difference in overall survival (OS) between the PARP inhibitors and controls, even in the BRCA mutation group. Little toxicity was reported in the rate of treatment-related AEs in PARP inhibitor group compared with controls.

CONCLUSIONS: In conclusion, PARP inhibitors do well in improving PFS with little toxicity, especially in patients with BRCA deficiency.

CLINICAL IMPLICATIONS: Today, many traditional anti-cancer drugs are able to kill tumor cells, but their toxicity to normal cells restricts their clinical application. PARP inhibitors target DNA repair, and kill cancer cells through “synthetic lethality”. In this way, PARP inhibitors are applicable across various cancers, improving the efficacy and reducing the toxicity of individualized therapies.

DISCLOSURE: The following authors have nothing to disclose: Zhengqiang Bao, Chao Cao, Bao-ping Tian, Zhihua Chen, Wen Li, Huahao Shen, Songmin Ying

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543